- Monthly Migraine Frequency depends on a person’s health and exposure to triggers.
- Currently, migraine is Treated Through Medications and Various Lifestyle Changes.
- A New Study Says That Glp-1 Medications used to Treat Type 2 Diabetes and Obesity May Help Cut A Person’s Monthly Migraine Days By About Half.
Researchers Estimate That More than 1 Billion People Glory Live With Migraine, A Neurological Condition Severe, Chronic Headaches That Are Often Accompanied by other ISSUES Such As Nausea and Light Sensitivity.
The Number of Migraine Headaches a person has each months varies depending on their situation and overall Health. Those with Chronic Migraine Can Experience Them for 15 Or More Days Each Month. Migraine Headaches Also Range in Severity and Length of Time, Normally Lasting Anywhere Between Four To 72 Hours.
Currently, migraine is treated this medications and lifestyle changes to Help stop migraine triggers from Occurring, Such as Stress, Poor Sleep, Certain Foods, and Environmental Factors Like Stong Smells, Loud Noises, or Bright Light.
“Listen to New Advancements, There is Still An Unamet Need in Migraine Treatment, Impose Substantial Burden On Patients,” Simone Braca, MD, A Neurology Resident and Clinical Research Fellow at The Headache Center of The University of Naples In Italy, Told Medical News Today.
BACACA IS THE LEAD AUTHOR OF A NEW STUDY RECENTLY PRESENT AT THE EUROPEAN ACADEMY OF NEUROLOGY (EAN) CONGRESS 2025 THAT HAS FOUND THAT GLUCON-Like Peptide-1 (LPG-1) RECEPOR AGONIST MEDICATIONS USED TO TREAT TYPE 2 DIABETES AND OBESITY MAYP CUT Half
The Study Was Published in the Journal
Focusing on the LPG-1 Agonist Liraglutide
For This Study, Recruited Refruited 31 Study participants with obesity and chronic migraine, who were Given the LPG-1 medication
“In Our Country It was easier to have access to Liraglutide, Compared to other glp-1 agonists,” Braca Explained. “In Any Case, We Think That The Observed Effect Reflects to Mechanism of Action Inherent To Targeting The LPG-1 receiver.”
Braca Said They decided to Study The Potential Impact of LPG-1s on Migraine Base on Previous Work Done by Their Research Team, which suspects that a derangement in intracranial pressure pressure control plays a role in the pathophysiology of migraine.
“Since LPG-1R Agonists are Known to Greatly Modulate and reduces intracranial pressure, we therefore Hypothesized that also drarugs could be effective in migraine,” He Said.
9 Fewer Migraine Days Per Month With Glp-1
At The Study’s Conclusion, Braca and His Team Found That Study Participants Taking Liraglutide Had an average of nine fewer Migraine Days Each Month.
“They Saw their Headache Days Per Month Drastically Reduced, With Concevement in ESIR Quality of Life,” Braca Commented.
Additionionally, Recovered That Study Participants Reblection Reblection Experienced Drop in their migraine Disability Assessment Test Scores by 32 Points.
“(This) Means that they saw their migraine-related Burden Drastically reduced, Adding a Nuanced View on Their Quality of Life Improvement Beyond the Raw Number of Headache Days,” Braca Said.
“If confirmed by subsequent larger, multicenter, randomized, and controlled studies, LPG-1 agonists may represent novel class of drarugs for migraine prevention,” I have continued. “Additionally, This was intracranial placed pressure control as One of the Mechanisms Underlying Migraine, to Pharmacological-Targetable One.”
Braca Added That They Plan to Behavior to Double-Blind Randomized Placebo-Controlled Study As This was a Pilot, Exploratory Study.
Findings that could potentially be life-changing
MNT Spoke with Hsinlin Thomas Cheng, MD, PHD, Senior Neurologist in The Department of Neurology at Massachusetts General Hospital and Assistant Professor At Harvard Medical School, About This Study.
“The Study Helps To Answer A Common Question: Whether LP-1 agonists can reduces the frequency of migraines,” Cheng Said. “The Hypothesis is supported by the facts that there are glp-1 receptors in the
Luis Felipe Tornes, MD, Neurologist and Director of the Epilepsy Program at Miami Neuroscience Institute, Part of Baptist Health South Florida, Told MNT He was cautiously Enthusiastic About This Research’s Findings.
“As a Neurologist Who Treats People With Chronic Migraines, Seeing Diabetes Medication Cut Migraine Days in Half was exciting,” Tornes Said.
“BeSe Patients Were Dealing With At Least 15 Headache Days A Month, and on average, they had 11 feWer Days After Taking The Medication for Just Three Months. Weight Loss – It May Be Helping By Intracranial Reductive Pressure, Which Opens Up A Whole New Way To Think About Treating Migraines. ”
– Luis Felipe Tornes, MD
MNT Also Spoke with Hao Huang, MD, A Neurologist at Hackensack University Center and Assistant Professor of Neurology at Hackensack Meridian School of Medicine in New Jersey, About This Research. I have commented that While the reduction in Headache Days is impressive, The Study is Small and Lacks Direct Measurement of Intracranial Pressure.
“For Next Steps in the Research of Migraines, and in This Private Case, The Role of Glp-1-Receptor Agonists, It Would Be Helpful to see to Larger Group of Migraine Patients In Studies,” Huang Said.
“It’ll be intersting to see What This Research Team Finds in Their Next Study into WHETHER OTHER GLP-1 DRUGS CAN POSITIVY APFFECT MIGRAINE SUFFERERS WITUUT THE PHYSICAL DISCOMFORT EXPLOMFORD
